A new oral antiviral drug candidate has been developed for the treatment of diseases caused by orthoparamyxoviruses, such as measles and croup syndrome, according to a study published by researchers in the Center for Translational Antiviral Research at Georgia State University. The paper in Science Advances identifies clinical candidate GHP-88310 for urgently needed, improved orthoparamyxovirus disease management in rodent and non-rodent animal models of infection. Orthoparamyxoviruses, such as human parainfluenzaviruses, measles virus and emerging henipaviruses, pose a significant threat to human health.
This article was originally published by MedicalXpress. For more details, images, and references:
Read Full Original Article ↗